H. Bhullar

First name

H.

Last name

Bhullar

Re, 3rd. L., Haynes, K., Ming, E. E., Ives, W., Horne, L. N., Fortier, K., et al. (2012). Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3318

View

Carbonari, D. M., Saine, M. E., Newcomb, C. W., Blak, B., Roy, J. A., Haynes, K., et al. (2015). Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3844

View

Saine, M. E., Carbonari, D. M., Newcomb, C. W., Nezamzadeh, M. S., Haynes, K., Roy, J. A., et al. (2015). Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol. http://doi.org/10.1186/s40360-015-0007-z

View

Saine, M. E., Gizaw, M., Carbonari, D. M., Newcomb, C. W., Roy, J. A., Cardillo, S., et al. (2017). Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4368

View

Re, L., Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q., et al. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000400

View

Lum, K. J., Newcomb, C. W., Roy, J. A., Carbonari, D. M., Saine, M. E., Cardillo, S., et al. (2017). Evaluation of methods to estimate missing days\textquoteright supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Eur J Clin Pharmacol. http://doi.org/10.1007/s00228-016-2148-4

View